Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2024
Reporting Period: Specific event date of October 24, 2024.
This filing details a mandatory prepayment received by Oramed from Scilex Holding Company ("Scilex") under a Senior Secured Promissory Note (Tranche A Note) originally issued in September 2023.
Key Financial Metrics
- Payment Received: Approximately $1,000,000 received on October 24, 2024.
- Total Repaid/Refinanced: $80,200,000 of the original $101,875,000 principal amount of the Tranche A Note has been repaid or refinanced as of this date.
- Remaining Principal: Approximately $21,675,000 (calculated as original principal less total repaid/refinanced).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for general revenue, profit, or operating cash flow metrics.
Material Changes
The primary material change is the reduction of the outstanding principal balance on the Tranche A Note due to a mandatory prepayment triggered by Scilex's recent financing activities. This follows a refinancing event on October 7, 2024, where $22,500,000 of the Tranche A Note was exchanged for Tranche B Notes and warrants, and an additional $2,500,000 was exchanged for rights under a Royalty Purchase Agreement.
Outlook, Risks, and Unusual Items
- Prepayment Trigger: The Tranche A Note requires mandatory prepayments of 70% of net cash proceeds Scilex receives from debt or equity financings, subject to conditions.
- Payment Priority: Under the "Agreement Among Holders," obligations for the new Tranche B Notes are subject to the prior payment in full of Tranche A Note obligations up to a defined "Maximum First Out Amount."
- Management Commentary: The filing confirms the receipt of funds as previously disclosed terms were executed but does not provide forward-looking guidance on future operations or clinical trials.
Investor Verification Checklist
- Verify the exact remaining principal balance of the Tranche A Note after the $1,000,000 payment.
- Review the "Maximum First Out Amount" definition in the Agreement Among Holders to understand the seniority of the remaining Tranche A debt versus the new Tranche B debt.
- Confirm the status of the Royalty Purchase Agreement and the value of the $2,500,000 principal exchange.
- Monitor Scilex's future financing activities, as they trigger further mandatory prepayments to Oramed.